 Decline of proteostatic mechanisms is a characteristic of aging.  Human amylin is a peptide prone to form aggregates in β-sheet conformation.  Amyloidogenic human amylin seems to be involved in Type 2 Diabetes pathogenesis.  Human amylin interferes with UPS and ALS leading to disturbances of proteostasis.  UPS and ALS both seem to play a role in human amylin degradation.
Introduction
Aging is a complex process involving multiple components affecting each other. Many theories exist trying to explain the intricate process. As a natural and universal process aging per se is not defined as a disease. However, aging is accompanied by the accumulation of cellular damage potentially resulting in age-related diseases influenced by genes as well as lifestyle and environmental factors. Studies in nematodes, fruit flies and mice revealed that genes involved in cellular stress response significantly affect aging [1] [2] [3] [4] [5] [6] [7] . Free radicals as well as non-radical reactive oxygen or nitrogen species (ROS and RNS), generated endogenously as a by-product of normal metabolism or exogenously due to environmental factors, contribute at least in part to the initiation of cellular stress. These species react with and damage cellular macromolecules, such as proteins, lipids and DNA. Oxidized or modified macromolecules accumulate and, in case of lipids and proteins, aggregate during aging due to reduced stress response able to affect further macromolecules [8] [9] [10] [11] [12] [13] [14] . Misfolded and aggregated proteins are linked to several degenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease or even cancer [15] .
Lipofuscin is one of the predominant aggregates, whose abundance correlates positively with increasing age [16] [17] [18] [19] [20] . It is composed of oxidized proteins and lipids as well as carbohydrates and small amounts of trace elements [21] [22] [23] . Several studies revealed interfering effects of lipofuscin with the main cellular degradation mechanisms by influencing proteasomal and also lysosomal activity as well as generation of ROS and induction of apoptosis [24] [25] [26] [27] [28] [29] . The occurrence of lipofuscin is connected to pathologies such as macular degeneration and Alzheimer's disease [30, 31] .
Besides oxidatively damaged protein aggregates, amyloids occur as a different type of aggregated proteins. Amyloidogenic proteins show β-sheet conformation, tightly linking these proteins to fibrillogenesis, but also amorphous aggregates can be formed [32, 33] . Currently, about 50 different proteins are determined forming such amyloidogenic structures, among them β-amyloid (Aβ) and human amylin [34, 35] . Until now, it is not clear, whether amyloid accumulation increases with age, although one human study showed an age-dependent increase in amylin-derived deposition in pancreatic islets [36] . Amylin secretion is also found to be altered in aged mice and plasma concentrations of amylin were shown to be increased in aged obese mice compared to young ones [37,
A C C E P T E D M
A N U S C R I P T 38]. In addition, amyloids are clearly linked to age-related diseases. The accumulation of Aβ is a wellknown hallmark of AD and, furthermore, human amylin was shown to accumulate in Type 2 diabetes (T2D) patients. Human amylin is known to have detrimental effects on pancreatic β-cells resulting in an impairment of β-cell functionality and finally in cell death [35, [39] [40] [41] .
Since the ubiquitin-proteasomal-system (UPS) and the autophagy-lysosomal-system (ALS), as the main cellular proteolytic systems, serve in maintaining proteostasis, both systems strongly influence cellular fate and consequently the aging process [42, 43] . Decreased activity of cellular turnover and proteostatic mechanisms are, amongst others, typical characteristics of aging leading to an accumulation and aggregation of non-degraded proteins. Studies revealed a decline in the amount of proteasomes in aging cells as well as in proteasomal activity in most tissues during aging possibly due to altered expression or modification of UPS enzymes or proteasomal subunits [8, 9, 16, 19, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] . Also autophagy seems to be in part impaired in age as a result of altered expression of ALS relevant proteins (reviewed in [54]). As mentioned before also age-related highly cross-linked protein aggregates such as lipofuscin interfere with UPS and ALS. The proteasome recognizes lipofuscin as a substrate trying to degrade this material. However, lipofuscin is non-degradable by the proteasome and therefore also inhibits this protease by preventing the degradation of other oxidized and non-functional proteins [25] . Lipofuscin is also found to accumulate in lysosomes and thereby decreases lysosomal enzyme activity [55] [56] [57] . Impaired proteolytic mechanisms -as a long-term consequence -lead to disturbed proteostasis and accumulation of non-degradable protein aggregates resulting in a cellular malfunction and cell death.
Studies also revealed altered UPS and ALS in AD. In AD patients and transgenic mice, impaired proteasomal ubiquitinating/deubiquitinating enzymes and alterations in proteasomal subunits as well as a defective autophagic flux are found. Because both systems play important roles in Aβ generation and clearance, dysfunctional UPS and ALS lead to an accumulation of aggregated Aβ (reviewed in [58]).
Since protein aggregates such as lipofuscin and Aβ have highly interfering effects on UPS and ALS, it is likely to assume that human amylin as a peptide susceptible to form amyloid aggregates affects proteolytic systems in the β-cell. This may lead to impaired β-cell functionality due to an imbalance in the proteome, which could contribute at least in part to the pathogenesis of T2D. Here, we review the known effects of human amylin on the mechanisms of protein degradation pathways and amylin's clearance by ALS/UPS in pancreatic β-cells.
Properties of amylin
Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino acid residue peptide, which is mainly co-expressed and co-secreted with insulin in a ratio between 1:10 and 1:100 (IAPP:insulin) in β-cells, but also in some other cell types [59] [60] [61] [62] [63] [64] [65] [66] [67] . Initially, IAPP is expressed as 89-amino acid PrePropeptide, which is subsequently cleaved to the Pro-peptide by peptidases in the endoplasmic reticulum (ER) and finally to the mature IAPP by prohormone convertase 2, prohormone convertase 1/3 and carboxypeptidase E in the Golgi apparatus. Additionally, the amidation of the C-terminal glycineresidue is required for the full biological activity of IAPP [68] [69] [70] [71] [72] . Figure 1A shows the amino acid sequences of human PrePro-IAPP, Pro-IAPP and mature IAPP with its cleaving and modification sites.
The amino acid sequences of IAPP and calcitonin gene-related peptide (CGRP) have strong similarities. Hence, IAPP belongs to the calcitonin peptide family. So far, there is no evidence for an amylin-specific receptor. However, some studies indicate the occurrence of calcitonin receptors
heterodimerized with receptor activity-modifying proteins (RAMPs), which have a high affinity for IAPP in the brain of mice and rats [73] [74] [75] [76] [77] [78] [79] .
IAPP has multiple physiological roles and acts in an endocrine as well as auto-and paracrine manner affecting glucose metabolism and energy balance. The physiological function has not been completely elucidated; current knowledge is summarized in Figure 2 .
Blood glucose levels are not only controlled by the uptake of glucose from blood into peripheral tissues such as skeletal muscle, but also by the entry of glucose from digested carbohydrates into the blood stream. It is well-known that insulin is responsible for facilitating the transport from the blood stream into insulin-dependent tissues (reviewed in [80] ). Amylin is partially responsible for controlling the other part, the uptake of glucose into the blood stream by slowing down gastric emptying [81, 82] . Therefore, IAPP may mediate centrally by direct action in the brain in a receptordependent way [78, 83] . However, IAPP may also mediate suppression of gastric emptying directly in the gut, since binding sites for IAPP are found in the stomach fundus of rats [84] and mRNA expression of IAPP is detected in the gastrointestinal tract [85] [86] [87] . Additionally, one study also reveals relaxation effects of IAPP on rat ileal smooth muscles [88] .
Regarding regulation of energy homeostasis, amylin controls food intake and body weight by acting as a satiation signal mediated directly in the central nervous system [89] (reviewed in [90] ). It is also effective as an adiposity signal to control energy expenditure [91, 92] . Some studies revealed that amylin is able to interact with and enhance the effects of other hormones in this context, for instance peptide YY [93] , insulin [94] and leptin [95] . Especially leptin shows a much higher impact on suppression of food intake and body weight in combination with amylin administration [96] [97] [98] . The impact of amylin on insulin and glucagon release is contrary. Some studies discovered that IAPP seems to inhibit insulin secretion [99] [100] [101] , whereas others were not able to show this effect [102] [103] [104] . Regarding glucagon, some publications reveal a, at least in part, suppressed secretion from islet α-cells leading to a decreased conversion of glycogen to glucose [105] [106] [107] [108] .
Amylin seems to have additional endocrine effects in the organism. It is assumed to influence bone metabolism due to the sequence similarity to CGRP by inhibiting osteoclast activity and stimulating osteoblast proliferation and activity [109, 110] . Furthermore, IAPP apparently plays a role in reninangiotensin-system and has vasodilatory effects [111, 112] . However, the physiological roles of amylin are still not fully understood and should be further investigated.
IAPP of most mammalian species, including humans (hIAPP), is prone to form fibrils in β-sheet conformation resulting in conversion to the above mentioned amyloids. In contrast, rodent IAPP (rIAPP) does not form such amyloidogenic structures due to the presence of proline-residues in certain positions of the amino-acid-sequence [113] [114] [115] . Infrared spectroscopy, electron microscopy and solidstate nuclear magnetic resonance studies revealed the following structural model of human amylin fibrils: Every fibril is composed of columns, which are built up by U-shaped IAPP monomers packed on top of each other. Due to the U-shaping, two parallel β-sheets are formed within every column, one N-terminal (residue 8-17) and one C-terminal (residue 25-37) β-sheet. Residues 18-22 form a loop between both β-sheets and a disulfide bond exists between cystein 2 and 7. Hydrogen bonds stabilize the monomers. Figure 1B shows a model of U-shaped so called "in-registered" organized hIAPPmonomers, what means an arrangement of the C-terminal sheets next to each other in an anti-parallel way, and Figure 1C of a hIAPP fibril [116] [117] [118] .
hIAPP-aggregates accumulate mainly extracellularly. Nevertheless, in β-cells small amounts were also found intracellularly [119, 120] . By now, several hypotheses of the cytotoxic mechanisms of human amylin on β-cells have been published, but none of the described cellular processes is fully
The cytotoxic effects range from membrane disruption, to ROS generation, induction of apoptosis, impact on inflammasome, ALS and UPS and suggested mechanisms via ER stress. In the last years, research increasingly focused on IAPP oligomers, since they are assumed to be more toxic than amorphous aggregates [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] . Figure 3 summarizes the most important hypothesized cytotoxic effects of hIAPP on β-cells.
Amylin and Ubiquitin-Proteasome-System
The UPS is besides the ALS one of the main proteolytic systems in mammalian cells. Both are involved in preservation of proteostasis and constantly adjust the proteome to maintain a functional set of proteins and thus cellular functionality. The UPS recognizes and degrades (oxidatively) damaged and dysfunctional proteins, therefore partially preventing the accumulation and aggregation of damaged proteins. Fully functional proteins, which are no longer needed or pass through a normal turnover, are also removed by the UPS. The proteasome is the most important cytosolic protease in mammalian cells, removing more than 90 % of the oxidatively damaged proteins [134, 135] . proteasome assay with extracts from human pancreatic islets after treatment with hIAPP [130] .
The 20S proteasome is the core particle consisting of multiple subunits forming four rings stacked on top of each other. The outer alpha rings are in charge of substrate recognizing and regulating the access of the substrates into the proteasomal chamber, where the inner beta rings provide their proteolytic activity. To form the 26S proteasome, so called 19S regulator subunits are necessary. Binding of one regulator to an alpha ring of the 20S proteasome leads to the formation of the 26S proteasome, whereas binding of two 19S regulator domains forms the 30S proteasome, in the literature often also termed as 26S proteasome. The regulator subunits modulate proteasomal activity and substrate specificity in an ATP-dependent way. Energy released by hydrolysis of ATP is needed for the unfolding of proteins, but not for the proteolytic degradation itself. Hence, the 26S and 30S are able to degrade natively folded and fully functional proteins, in contrast to the unbound 20S [134, [136] [137] [138] [139] [140] [141] .
Besides the 19S regulator, specific tags binding to the substrates are required for degradation of fully functional and natively folded proteins by 26S proteasome. Several ubiquitin molecules, a ubiquitously occurring protein comprised of 76 amino acids, form a short "polyubiquitin" chain, linked to the substrate. This system of highly specific substrate polyubiquitination and deubiquitination controlling proteasomal degradation, is strongly regulated by specific ubiquitination enzymes called E1, E2 and E3 and deubiquitination enzymes (DUBs), such as Ubiquitin carboxyterminal hydrolase L1 (UCH-L1) [142] [143] [144] [145] .
In contrast to the investigation of Casas et al., other studies showed controversial findings regarding proteasomal activity. Transduction of isolated human islets with adenoviruses expressing hIAPP did not show any differences in 20S proteasomal activity compared to rIAPP transduced cells, but both
resulted in an increase of proteasomal activity compared to non-transduced control cells. Furthermore, no differences in proteasomal activity could be observed in islets of hIAPP transgenic rats and wildtype rats [146] . In another study, treatment of RIN-m5F, a rat pancreatic insulinoma β-cell line, and isolated human pancreatic islets with hIAPP or rIAPP revealed inhibitory effects of both forms on proteasomal activity [147] .
Furthermore, microarray analysis reported a downregulation of cytosolic Heat-shock proteins (Hsp) 90AA1, 90AB1 and ER-related Hsp90B1 after hIAPP-treatment [130] . Hsp90 is a chaperone assisting in protein degradation by the 26S proteasome and preventing 20S proteasome inactivation due to oxidative stress. Downregulation of these chaperones could also contribute to the decline of proteasomal activity [148, 149] .
Impairment of the 26S proteasome normally leads to accumulation of ubiquitinated proteins. Indeed, an increased amount of ubiquitinated proteins in hIAPP-treated Min6 cells was found. Also hIAPP transgenic rats and hIAPP transduced INS 832/13, a rat insulinoma cell line, showed an accumulation of polyubiquitinated proteins in comparison to wildtype rats and rIAPP transduced cells [130, 146] , whereas hIAPP treatment of RIN-m5F cells did not result in an elevation of polyubiquitinated proteins [147] . An accumulation of ubiquitinated proteins may also be a hint for a deficiency of other UPS components, such as DUBs. UCH-L1, one of the DUBs, is an important enzyme in the UPS controlling the proteasomal entry of ubiquitinated proteins by deubiquitinating and thereby preventing substrate degradation [144, 145] . Individuals with type 2 diabetes show diminished levels of UCH-L1 in combination with a decreased proteasomal activity and consequently an accumulation of polyubiquitinated proteins [146] . hIAPP transgenic rats showed decreased mRNA levels of UCH-L1 and a marked decline in UCH-L1 protein levels. Furthermore, hIAPP or rIAPP transduced INS 832/13 cells confirmed downregulation of UCH-L1 as a specific event for amyloidogenic hIAPP, but not for non-amyloidogenic rIAPP. Chemical inhibition as well as knockdown of UCH-L1 in INS 832/13 led to increased apoptosis, measured by cleavage of caspase-3 and its substrate Poly(ADP-ribose) polymerase (PARP). Furthermore, elevated ER stress, shown by raised levels of CCAAT-enhancerbinding protein homologous protein (CHOP) and diminished levels of eukaryotic initiation factor 2 (eIF2) were detected. Both hIAPP and rIAPP transduction in addition to UCH-L1 knockdown further increased apoptosis compared to scramble-transfected cells, hIAPP to a greater extent than rIAPP. This indicated that non-amyloidogenic rIAPP is also harmful under certain conditions possibly due to the higher protein burden by IAPP transduction in the cells [146] .
Another important question besides the effects of hIAPP on the UPS is, whether the proteasome is responsible for the degradation of IAPP. Therefore, studies with proteasome activity modulators were performed. Inhibition of the proteasome with lactacystin and epoxomicin resulted in an increase of hIAPP content and toxicity in hIAPP-treated in Min6 and RIN-m5F cells. Toxicity was measured by analysis of apoptosis (caspase-3 cleavage) and by viability tests. Conversely, stimulation of the proteasome with protein activator 28 (PA28) was reducing the cytotoxic effects of hIAPP. Furthermore, inhibition of the proteasome also resulted in an elevated amount of endogenously expressed rIAPP. This led to the assumption that the proteasome plays at least in part a role in degradation of both uptaken hIAPP and also endogenous non-amyloidogenic rIAPP [130, 147] .
To confirm the role of the proteasome in hIAPP degradation, immunoprecipitation studies were performed. Interactions between hIAPP and the α4 subunit of the 20S proteasome were found mainly in the nucleus of RIN-m5F cells and of human islets. The question arises, whether IAPP is degraded by 20S proteasome or also by 26S proteasome in an ubiquitin-dependent way. In vitro-studies revealed that ubiquitination of IAPP is not necessarily required for the interaction of hIAPP with 20S proteasome. In contrast, immunoconfocal microscopic studies reported a strong colocalization of
hIAPP and ubiquitin in hIAPP treated cells and human islets. Internally expressed hIAPP was also shown to be ubiquitinated. Additionally, rpn8, an important regulatory subunit of the 19S complex, coprecipitated with hIAPP and α4. hIAPP further colocalized with Hsp70 and Hsp90. These results indicated that an ubiquitin-dependent interaction cannot be excluded. Furthermore, an additional in vitro study showed proteasomal degradation of hIAPP in both aggregation-inhibiting and aggregationprone conditions leading to the assumption that aggregation of hIAPP is not required for its degradation by the proteasome [147, 150] .
In summary, the UPS seems to play a role in the turnover of both hIAPP and rIAPP. Dysfunctional proteasomal degradation mechanisms, as they occur during aging or due to covalently cross-linked protein aggregates, could therefore lead to the accumulation of ubiquitinated proteins and amyloidogenic aggregates such as hIAPP, exacerbating the toxic cellular effects of human amylin. Human amylin apparently impairs the UPS, more precisely proteasomal activity and the expression of cytosolic chaperone Hsp90 and deubiquitination enzyme UCH-L1.
Amylin and Autophagic-Lysosomal-System
The second important cellular proteolytic system besides the UPS is the ALS. A major characteristic is the dynamic membrane reorganization resulting in the uptake and degradation of substrates. The ALS is able to incorporate protein aggregates, macromolecules, also from the extracellular space, and even whole cell organelles, while the UPS is only capable to degrade proteins. It also plays an important role in a wide array of cellular processes, such as differentiation, growth control, inflammation, immune system, energy metabolism [151] [152] [153] [154] [155] [156] .
Currently three different types of autophagy, macroautophagy, microautophagy and chaperonemediated autophagy, which differ in the pathways and mechanisms of substrate delivery to lysosomes, are described. During macroautophagy, cytosolic substrates are incorporated by a sequestering organelle -the phagophore or isolation membrane -, which develops to the autophagosome by expanding and sealing. Completing autophagosome formation is followed by fusion with lysosomes, content release and degradation by lysosomal enzymes. Macroautophagy is in comparison to the other autophagy types highly inducible and is regulated by a variety of signaling pathways, which enable appropriate response to different environmental conditions. Atg proteins (autophagy related proteins) are involved in these mechanisms by forming complexes leading to recruitment and induction of downstream Atg proteins. During microautophagy the lysosomes invaginates cytosolic material resulting in vesicle budding into the lysosomal lumen and its subsequent degradation. The third type is chaperone-mediated autophagy (CMA). Chaperones such as Hsc70 (Heat shock cognate 70) bind to substrates containing the amino acid sequence KFERQ and transfer them to the lysosome leading to the translocation of the substrate into the lysosomes mediated by co-chaperones, such as Hsp90, and lysosome-associated membrane protein type 2A (LAMP2A). For a more detailed description of autophagic mechanisms see special reviews [157] [158] [159] . insulinoma cell lines), transgenic rats and transgenic mice also showed an increase in autophagosome formation compared to rIAPP [131, 161] . Rivera et al. additionally described an elevated occurrence of autophagosomes in rIAPP transduced INS 832/13 cells compared to non-transduced cells, but to a much lesser extent compared to hIAPP transduction [131] . The question arises, if this increase in autophagosomes is due to an increased autophagic flux and consequently an increased autophagosome formation or if impaired lysosomal degradation is the underlying reason.
The results adressing this question are controversial. p62, also called sequestosome 1 or SQSTM1, is an important macroautophagy receptor serving for the delivery of the substrate to the autophagosome. The substrate, which is ubiquitinated by E3, binds to p62 and the p62/substrate-complex is then uptaken by the autophagosome mediated by LC3. In hIAPP treated INS-1 cells, transduced INS 832/13 cells and transgenic mice p62 protein levels were not affected indicating that the lysosomal activity is not affected and autophagosome formation is induced [161] . In contrast, elevated p62 protein levels were detected in hIAPP transgenic rats compared to wildtype rats. However, mRNA levels remained unchanged. This led to the different assumption that lysosomal degradation is decreased leading to an accumulation of p62. hIAPP transgenic mice showed an increase of both p62 mRNA and protein levels compared to rIAPP. However, mRNA level increase was less distinctive than p62 protein levels. In contrast, studies with hIAPP transduced INS 832/13 revealed an increase of p62 followed by a rapid decrease after 36 and 48 hours. This was in parallel accompanied by apoptosis induction leading to the hypothesis that p62 could have a possible role in β-cell survival [131] .
A possible explanation for the decreased lysosomal activity may be the ability of toxic hIAPP oligomers to disrupt cellular membranes [121, 123] . Lysosomal membranes could be punctured by spiky hIAPP structures leading to an increase of the lysosomal pH. Since the lysosomal enzymes show maximum activity at acidic pH, degradation of the cargo by these enzymes may consequently be disturbed [162] . Rupture of the lysosomal membrane may also result in the release of the enzymes leading to apoptosis [163] .
To test, whether autophagy plays a role in the degradation of toxic hIAPP, studies with autophagy modulators were performed. Inhibition of lysosomal proteases with pepstatin A increased hIAPPinduced apoptosis in transduced cells and IAPP content in INS 832/13 cells and human islets. Also knockout of Atg7 leading to autophagy deficiency, resulted in increased hIAPP induced apoptosis compared to rIAPP treatment [131, 150, 161] . In contrast, stimulation of autophagosome formation by rapamycin, an inhibitor of the mTOR (mammalian target of rapamycin) signaling pathway, reduced hIAPP-induced apoptosis and IAPP content. These changes in intracellular IAPP content were not a consequence of an altered IAPP expression or secretion, what indicated a role of autophagy for IAPP degradation. Interestingly, insulin content was not affected. Thus, autophagy seems to regulate cellular content of IAPP. Rivera et al. further confirmed that IAPP became polyubiquitinated, possibly resulting in degradation by p62-dependent autophagy [131, 150] . However, ubiquitination of proteins could also be a hint for degradation by 26S proteasome.
Studies from Singh et al. indicated that intracellular and extracellular IAPP may be eliminated by different clearance mechanisms. In contrast to the studies mentioned before, they treated RIN-m5F cells with hIAPP and rIAPP by adding the compounds to the culture medium. After cellular uptake, IAPP was mainly translocated into the nucleus and only small amounts colocalized with lysosomes. Autophagy inhibition with pepstatin A showed no significant change in cellular IAPP content [147] .
The suggested protective role of p62 was confirmed by studies with transduced cell lines and transgenic mice, where both hIAPP and, to a lesser extent, also rIAPP immunoprecipitated with p62. Furthermore, immunoprecipitation of IAPP with p62 was exclusively found in insoluble fractions of
cell lysates from hIAPP-transgenic and not from rIAPP-transgenic mice. This result, in addition to positive thioflavin S staining in p62-inclusions, revealed that p62 inclusions also contain insoluble forms of hIAPP. Further investigations reported that p62 inclusions are surrounded by components of the ALS, more precisely autophagosomes and lysosomes. This could be a hint that hIAPP and rIAPP are degraded by p62-dependent autophagy and furthermore that p62 protects the cell from toxic hIAPP species. Additional experiments reported that β-cells of hIAPP transgenic mice containing p62-positive inclusions showed less binding of the specifically oligomeric hIAPP recognizing antibody A11, confirming the protective role of p62 from toxic oligomers [150] . Knockdown of p62 with shRNA increased hIAPP-mediated apoptosis in INS 832/13 cells, whereas an overexpression of p62 led to a decrease of hIAPP-induced apoptosis [131] .
Summarized, it was shown that ALS plays a role in the clearance of amylin and therefore in diminishing the cytotoxic effects of human amylin. Since autophagic flux seems to be decreased in age [164] , the detrimental cellular effects of hIAPP are likely to be exacerbated due to dysfunctional autophagy as shown in studies with chemical inactivation and induction of autophagy and p62 expression. Human amylin also seems to interfere with autophagic pathways. So far, it is unknown, if autophagosome accumulation is the consequence of an increased formation or an impaired lysosomal degradation due to hIAPP burden.
Conclusion
Current knowledge about the effects of amylin on UPS and ALS and the role of both degradation systems in amylin turnover is limited. Nevertheless, there is evidence that UPS as well as ALS are involved in the clearance of amylin, but are also affected by amylin, especially by the human one (summarized in Figure 4) . However, the mechanisms causing disturbances in both proteolytic pathways are unknown. Studies investigating the UPS and ALS in response to hIAPP are incoherent possibly due to different methods and models used. UPS and ALS as the main proteolytic systems influence the cellular fate and therefore also the aging process. A decline of both systems is a wellknown characteristic of aging. So far, it is not fully understood, if hIAPP aggregates accumulate during aging. However, it is reasonable that the age-dependent decrease of proteolytic activity has an impact on the detrimental effects of human amylin especially in β-cells and therefore on T2D pathogenesis. IAPP has endocrine as well as auto-/paracrine effects. It is involved in slowing down gastric emptying and reducing food intake, by acting in the brain and probably also in the stomach, and consequently reduces body weight. For that, amylin also works synergistically with other hormones such as leptin. Due to its similarity to the calcitonin-gene related peptide, it affects also bone metabolism by decreasing osteoclast activity. Additionally, amylin influences vasodilation and the renin-angiotensin-system. Amylin's autocrine effects on pancreatic β-cells are controversial. It seems to reduce glucagon release. However, insulin secretion was found to be decreased as well as unaltered. 
